vs
Side-by-side financial comparison of ARROWHEAD PHARMACEUTICALS, INC. (ARWR) and Lanvin Group Holdings Ltd (LANV). Click either name above to swap in a different company.
ARROWHEAD PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($264.0M vs $144.1M, roughly 1.8× Lanvin Group Holdings Ltd).
Arrowhead Pharmaceuticals, Inc. is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead's products in development act through RNA interference (RNAi) mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease.
Lanvin is a French luxury fashion house founded in 1889 by Jeanne Lanvin in Paris. It is the oldest French fashion house still in operation. Since 2018, it has been a subsidiary of Shanghai-based Lanvin Group. Lanvin Group includes Lanvin, Sergio Rossi, Wolford, St. John Knits, and Caruso.
ARWR vs LANV — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $264.0M | $144.1M |
| Net Profit | $30.8M | — |
| Gross Margin | — | 53.9% |
| Operating Margin | 15.5% | -60.5% |
| Net Margin | 11.7% | — |
| Revenue YoY | 10461.3% | — |
| Net Profit YoY | 117.8% | — |
| EPS (diluted) | $0.22 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $264.0M | — | ||
| Q2 25 | — | $144.1M | ||
| Q2 24 | — | $184.7M | ||
| Q2 23 | — | $231.7M |
| Q4 25 | $30.8M | — | ||
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | — | — | ||
| Q2 25 | — | 53.9% | ||
| Q2 24 | — | 57.5% | ||
| Q2 23 | — | 58.5% |
| Q4 25 | 15.5% | — | ||
| Q2 25 | — | -60.5% | ||
| Q2 24 | — | -35.0% | ||
| Q2 23 | — | -32.5% |
| Q4 25 | 11.7% | — | ||
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | $0.22 | — | ||
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $715.0M | $32.1M |
| Total DebtLower is stronger | — | $290.3M |
| Stockholders' EquityBook value | $568.4M | $-116.4M |
| Total Assets | $1.6B | $632.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $715.0M | — | ||
| Q2 25 | — | $32.1M | ||
| Q2 24 | — | $19.3M | ||
| Q2 23 | — | — |
| Q4 25 | — | — | ||
| Q2 25 | — | $290.3M | ||
| Q2 24 | — | $136.4M | ||
| Q2 23 | — | — |
| Q4 25 | $568.4M | — | ||
| Q2 25 | — | $-116.4M | ||
| Q2 24 | — | $100.1M | ||
| Q2 23 | — | — |
| Q4 25 | $1.6B | — | ||
| Q2 25 | — | $632.1M | ||
| Q2 24 | — | $731.8M | ||
| Q2 23 | — | — |
| Q4 25 | — | — | ||
| Q2 25 | — | — | ||
| Q2 24 | — | 1.36× | ||
| Q2 23 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $13.5M | $-75.1K |
| Free Cash FlowOCF − Capex | $11.3M | — |
| FCF MarginFCF / Revenue | 4.3% | — |
| Capex IntensityCapex / Revenue | 0.8% | — |
| Cash ConversionOCF / Net Profit | 0.44× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $13.5M | — | ||
| Q2 25 | — | $-75.1K | ||
| Q2 24 | — | $-36.2K | ||
| Q2 23 | — | $-62.8K |
| Q4 25 | $11.3M | — | ||
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | 4.3% | — | ||
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | 0.8% | — | ||
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | 0.44× | — | ||
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
